Related Experiment Video

Updated: Aug 21, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Pragmatic target discovery from novel gene to functionally defined drug target: the interleukin-1 story

Stuart McRae Allan1

  • 1School of Biological Science, University of Manchester, United Kingdom.

Methods in Molecular Medicine
|September 30, 2004
PubMed

Insights

Interleukin-1 (IL-1) may drive neurodegeneration after stroke. Blocking IL-1 with IL-1 receptor antagonist (IL-1ra) reduced cell death in rodent studies, suggesting IL-1ra as a potential neuroprotective stroke treatment.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • The pro-inflammatory cytokine interleukin-1 (IL-1) is implicated in acute neurodegenerative changes post-stroke.
  • Evidence primarily comes from rodent models showing reduced ischemic cell death with IL-1 receptor antagonist (IL-1ra).

Purpose of the Study:

  • To explore the role of IL-1 as a mediator of neurodegeneration following stroke.
  • To investigate the potential therapeutic application of IL-1ra in stroke and other neurodegenerative conditions.

Main Methods:

  • Review of experimental studies, particularly in rodent models.
  • Analysis of the effects of IL-1 receptor antagonist (IL-1ra) administration.

Main Results:

  • Administration of IL-1ra significantly reduced ischemic cell death in experimental stroke models.
  • IL-1's mechanisms of action involve complex effects on various brain cells.

Conclusions:

  • Interleukin-1 (IL-1) is a key mediator in acute stroke-related neurodegeneration.
  • IL-1 receptor antagonist (IL-1ra) shows promise as a neuroprotective therapy for stroke.

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...